Evoke Pharma Inc (EVOK)
4.33
-0.17
(-3.78%)
USD |
NASDAQ |
Nov 22, 16:00
4.22
-0.11
(-2.54%)
After-Hours: 20:00
Evoke Pharma Revenue (TTM): 8.617M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.617M |
| June 30, 2024 | 7.526M |
| March 31, 2024 | 6.106M |
| December 31, 2023 | 5.181M |
| September 30, 2023 | 4.301M |
| June 30, 2023 | 3.570M |
| March 31, 2023 | 2.901M |
| Date | Value |
|---|---|
| December 31, 2022 | 2.509M |
| September 30, 2022 | 2.073M |
| June 30, 2022 | 2.171M |
| March 31, 2022 | 1.946M |
| December 31, 2021 | 1.618M |
| September 30, 2021 | 1.280M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
1.280M
Minimum
Sep 2021
8.617M
Maximum
Sep 2024
3.831M
Average
2.901M
Median
Mar 2023
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| MEI Pharma Inc | -- |
| Revance Therapeutics Inc | 256.94M |
| NovaBay Pharmaceuticals Inc | 13.84M |
| Palatin Technologies Inc | -- |